Stoke Therapeutics, Inc. (NASDAQ: STOK) is highlighted as one of the Hot Growth Stocks to Invest in Now. Analyst Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on STOK with a $35 price target. The company’s drug, Zorevunersen, shows promising potential in treating Dravet syndrome, with long-term reduction in major motor seizure frequency and cognitive improvements. Zorevunersen differentiates itself with a focus on symptomatic relief. Stoke Therapeutics develops RNA-based medicines to increase protein expression for various diseases, with Zorevunersen as a lead drug. There is no promotional content in this article.

Read more at Yahoo Finance: H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)